An interventional study of Galactose and Glucose in Cardiovascular Risk Factor and Lipemia, sponsored by University of Bath. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-24.
Sponsored by University of Bath · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Hyperlipidemias with a site in United Kingdom — 3 open to participants now, 4 under way, 3 of them phase 3. Hyperlipidemias · United Kingdom.
Among the 40 studies in Hyperlipidemias with a site in United Kingdom, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2018, is one of 10 with no phase, and was the 29th registered.
863 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →3 of the 40 studies in Hyperlipidemias with a site in United Kingdom are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18–70
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 35 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 88 across 736 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 39 interventional studies, 7,200 across the 1 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 40 have an industry lead sponsor. The 10 most frequent:
University of Bath is the lead sponsor of 94 studies on the registry; 20 are open to participants now.
University of Bath has 2 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Hyperlipidemias with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to assess the postprandial triglyceride response to the ingestion of a high-fat meal with co-ingestion of either galactose, or glucose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
Dietary Supplement: Galactose
Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
Dietary Supplement: Glucose
Postprandial increase plasma triglyceride concentrations
Incremental area under the curve (iAUC) of plasma triglyceride concentrations
Time frame: 5 hours
Postprandial plasma insulin concentrations
Incremental area under the curve (iAUC) of plasma insulin concentrations
Time frame: 5 hours
Postprandial plasma glucose concentrations
Incremental area under the curve (iAUC) of plasma glucose concentrations
Time frame: 5 hours
Postprandial plasma non-esterified fatty acid concentrations
Postprandial area under the curve of non-esterified fatty acid concentrations
Time frame: 5 hours
Postprandial plasma lactate concentrations
Incremental area under the curve (iAUC) of plasma lactate concentrations
Time frame: 5 hours
Postprandial subjective hunger ratings
Postprandial area under the curve of hunger ratings measured by visual analogue scales (0-100 mm)
Time frame: 5 hours
Postprandial subjective fullness ratings
Postprandial area under the curve of fullness ratings measured by visual analogue scales (0-100 mm)
Time frame: 5 hours
Postprandial subjective satisfaction ratings
Postprandial area under the curve of satisfaction ratings measured by visual analogue scales (0-100 mm)
Time frame: 5 hours
Postprandial prospective food consumption ratings
Postprandial area under the curve of prospective food consumption ratings measured by visual analogue scales (0-100 mm)
Time frame: 5 hours
Postprandial overall appetite ratings
Postprandial area under the curve of overall appetite ratings measured by visual analogue scales (0-100 mm)
Time frame: 5 hours
Plan to share: No — Raw data will be made available online upon publication in a peer-reviewed journal.
Ran from Feb 2018 to primary completion in May 2018, 3 months.
Of 166 non-industry interventional studies with no phase under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 3 months is below that.
Counting every sponsor, half of 171 studies reached it within 15 months; a quarter within 7 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Galactose
University of Bath